Sanofi Pasteur Sa

Sanofi Pasteur Inc.

Aventis Pasteur S.a.

Boehringer Ingelheim Animal Health USA Inc.

Pasteur Merieux Serums Et Vaccins

Pasteur Merieux Serums & Vaccins

Boehringer Ingelheim Vetmedica Gmbh

Jean Haensler

Pascal Chaux

Bruno Guy

Sylvie Pichon

Joel Patarin

Monique Moreau

Joël Patarin

Fabienne Piras-Douce

Philippe Talaga

Scott Gallichan

Noëlle Mistretta

Marie Garinot

Rafaela Dumas

Valentin Valtchev

Marie-Jose B Quentin-Millet

Guillaume Rigaut

Jorge Ronco

Francois Dalencon

Patricia Probeck-Quellec

Yannick Mathieu

Christine Michele Pierrette Andreoni

Marie-Françoise Klucker

Alexis Guy André Lucien Parisot

Elisabeth Sauzeat

Patricia Probeck-Quelleec

Ausra Mancevski

Nathalie Reveneau

Jin Su

Benedicte Lebeau

Karelle De Luca

Lydie Remolue

Jean-François Cotte

Véronique Chambon

Emmanuelle Trannoy

Nicolas Burdin

Bénédicte Lebeau

François Dalencon

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.

Immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants

The invention relates to an immunogenic composition comprising an HCMV gB antigen, an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a Th1-inducing adjuvant. If further relates to the immunogenic composition for use as an HCMV vaccine.

Human cytomegalovirus immunogenic composition

The invention relates to an immunogenic composition comprising an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a TH1-inducing adjuvant. It further relates to the immunogenic composition for use as an HCMV vaccine.

A vaccine composition comprising at least one antigen and one adjuvant, characterized in that the adjuvant comprises sterile-filterable nanoparticles comprising pseudo-boehmite and polyacrylate.

Vaccine composition with aluminium hydroxide nanoparticles

The invention relates to a thermoreversible oil-in-water emulsion comprising:

Thermoreversible oil-in-water emulsion

The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as 'MOMP'), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of(e.g.,, orMoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of. The invention also provides methods of inducing an immune response to aspecies (e.g.,) in a subject, by administering to the subject a composition of the invention.

Immunogenic compositions

The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) ofor a lipidated fragment thereof; or (ii) LPS and the lipidated TbpB ofor a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB ofor a lipidated fragment thereof; in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB ofor a lipidated fragment thereof is omitted; as well as vaccine compositions thereof. The LPS may, for example, be the LOS of a non-enteric Gram-negative bacterium such as

Method for adjuvanting lipopolysaccharide (LPS) of gram-negative bacteria

The present invention relates to a pharmaceutical composition comprising at least one vaccine antigen, which also comprises at least one phosphoric ester derivative of phosphatidylcholine having the structure: in which:

Vaccine composition

An amphipathic compound including a sterol-derived lipophilic grouping bound to a cationic grouping for use as an adjuvant in the delivery of a vaccine composition. In a particular embodiment, the lipophilic grouping is a cholesterol derivative and the cationic grouping is a quaternary ammonium or a protonatable amine. A vaccine composition including one or more antigens with at least one amphipathic compound having a sterol-derived lipophilic grouping bound to a cationic grouping, is also disclosed.

Adjuvant for a vaccine composition

The invention concerns an oil-in-water immunostimulant emulsion comprising an aqueous phase and an oil phase, characterised in that it further comprises an immunostimulant polynucleotide whereof at least part is covalently bound to at least a lipid molecule. The invention also concerns a vaccine composition comprising such an emulsion as immunoadjuvant.

Immunostimulant emulsion

The invention relates to a pharmaceutical composition intended for inducing in a host mammal a protective immune response against an antigen, at a mucosal effector site, which comprises at least two identical or different products each containing an inducing agent for the immune response, selected from the antigen and, provided the antigen is protein in nature, an expression cassette capable of expressing the antigen, for a concomitant or consecutive administration; one of the products being formulated so as to be administered via the nasobuccal route so that the inducing agent is targeted to the inducer site(s) for an immune response in the naso-oropharynx or the salivary glands, the other product being formulated so as to be administered via a suitable mucosal route other than the nasal route, so that the inducing agent is targeted to the inducer site(s) for an immune response at the effector site at which the immune response is sought. Optionally, such a composition can also comprise a third product, identical to or different from the first two, formulated for systemic administration.

Methods for inducing a mucosal immune response

Use of a cationic amphipathic compound as a transfection agent, vaccine

Growing community of inventors

Grezieu La Varenne, France

Jean Haensler